Although advances in treatment have permitted patients with systemic lupus erythematosus (SLE) to live longer, the rates of several types of cancers in these patients appear to be increasing.We used a prospective study to investigate the prevalence and features of thyroid cancer in SLE patients.The prevalence of thyroid cancer in 153 unselected SLE patients was compared with that in two population-based, gender- and age-matched control groups: 1) 459 subjects from an iodine-deficient area (iodine-deficient control) and 2) 459 subjects from an iodine-sufficient area (iodine-sufficient control). Thyroid function was assessed by measuring circulating thyroid hormones and autoantibodies, thyroid ultrasonography, and where necessary, fine-needle aspiration cytology.The levels of circulating TSH, and anti-thyroglobulin and anti-thyroperoxidase antibodies were significantly higher in SLE patients (P < 0.001 for all). In addition, patients with SLE also exhibited a higher prevalence of hypothyroidism (P < 0.001). Five cases of papillary thyroid cancer were detected among SLE patients, whereas no cases were observed among iodine-deficient controls (P = 0.001), and only one case was observed among iodine-sufficient controls (P = 0.001). Among SLE patients with confirmed thyroid cancer, 80

作者：Alessandro, Antonelli；Marta, Mosca；Poupak, Fallahi；Rossella, Neri；Silvia Martina, Ferrari；Anna, D'Ascanio；Emiliano, Ghiri；Linda, Carli；Paolo, Miccoli；Stefano, Bombardieri

来源：The Journal of clinical endocrinology and metabolism 2010 年 95卷 1期